GlassScriptPhysician profile
Cherif Boutros
NPI 1912105495
$1,270.23
in general payments reported to CMS, 2019-2025
19 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $20.67 · 2021: $95.98 · 2022: $249 · 2023: $411 · 2024: $208 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.15 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galvanize Therapeutics, INC | $177.03 | 2024 | Aliya System |
| Eisai INC. | $158.23 | 2019-2023 | |
| Exelixis INC. | $137.21 | 2021-2023 | Cabometyx |
| Merck Sharp & Dohme LLC | $128.02 | 2019-2023 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $116.45 | 2023-2025 | Imfinzi, Enhertu |
| Pharmacyclics LLC, An Abbvie Company | $103.72 | 2021-2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $75.26 | 2019-2023 | Opdivo |
| Glaxosmithkline, LLC. | $67.97 | 2021-2022 | |
| Amgen INC. | $41.79 | 2023 | Lumakras |
| Tesaro, INC. | $37.51 | 2019 | |
| Pharmacosmos Therapeutics INC. | $36.82 | 2023 | Monoferric |
| Alexion Pharmaceuticals, INC. | $30.49 | 2024 | Ultomiris |
| Histosonics, INC. | $29.78 | 2025 | |
| Daiichi Sankyo INC. | $29.47 | 2023 | Enhertu |
| Array Biopharma INC | $24.51 | 2023 | Paxlovid, Braftovi, Comirnaty |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $20.67 | 2020 | |
| Servier Pharmaceuticals LLC | $19.25 | 2022 | |
| Organon LLC | $18.20 | 2023 | Renflexis, Ontruzant |
| W. L. Gore & Associates, INC. | $17.85 | 2025 | Gore Synecor Biomaterial |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherif Boutros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.